Pilot Randomized Trial of Bupropion for Adolescent Methamphetamine Abuse/Dependence

Heinzerling, Keith G.; Gadzhyan, Janette; Oudheusden, Henry van; Rodriguez, Felipe; McCracken, James T.; Shoptaw, Steven

doi:10.1016/j.jadohealth.2012.10.275

Cited by 23 publications

(23 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Four different psychostimulant therapies were examined in the included studies—modafinil [24, 34, 35], bupropion [12, 13, 21, 22, 30, 33], methylphenidate [25–28, 31, 32], and dexamphetamine/dextroamphetamine [23, 29]. …”

Section: Resultsmentioning

confidence: 99%

“…Furthermore, two other studies included participants with a diagnosis of amphetamine dependence alone and comorbid attention-deficit hyperactivity disorder (ADHD) [25, 26]. There was only one trial conducted in adolescents [33], while the remaining trials were within adult samples, 18–65 years of age. The adolescent study was conducted among participants with ≤18 days of methamphetamine use in the month prior to baseline interview [33].…”

Section: Resultsmentioning

confidence: 99%

“…There was only one trial conducted in adolescents [33], while the remaining trials were within adult samples, 18–65 years of age. The adolescent study was conducted among participants with ≤18 days of methamphetamine use in the month prior to baseline interview [33]. Two other studies were conducted among low-frequency adult methamphetamine users (≤29 days in the month prior to baseline interview) [12, 13].…”

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

Efficacy and safety of psychostimulants for amphetamine and methamphetamine use disorders: a systematic review and meta-analysis

et al. 2016

View full text Add to dashboard Cite

BackgroundAmphetamine and methamphetamine use disorders are associated with severe health and social consequences. No pharmacological therapy has been approved for the treatment of these disorders. Psychostimulants can act as maintenance-like therapies for managing substance use among these patients.The aim of this study is to evaluate the literature examining the efficacy and safety of psychostimulant agents for increasing abstinence and treatment retention among patients with amphetamine and methamphetamine use disorders.MethodsWe searched MEDLINE, EMBASE, PsycInfo, Cochrane Central, and CINAHL from inception to August 2016. Selection of studies, data extraction, and risk of bias assessment were conducted independently by two reviewers. We conducted meta-analyses to provide a pooled summary estimate for included trials and report the review according to PRISMA guidelines.ResultsWe identified and selected 17 studies with 1387 participants. Outcome reporting across trials was inconsistent, and the overall quality of evidence was very low due to high risk of bias and indirectness. A meta-analysis of five trials (642 participants) found no effect of psychostimulants for end-of-study abstinence (odds ratio = 0.97, 95% confidence interval 0.65 to 1.45). Additionally, the pooled estimate from 14 studies (1184 participants) showed no effect of psychostimulants for treatment retention (odds ratio = 1.20, 95% confidence interval = 0.91 to 1.58). The incidence of serious adverse events did not differ between intervention and placebo groups based on qualitative reports from trials.ConclusionsQuantitative analyses showed no effect of psychostimulants for sustained abstinence or treatment retention. We also identified the need for more rigorous studies in this research area with clinician and patient important outcomes.Electronic supplementary materialThe online version of this article (doi:10.1186/s13643-016-0370-x) contains supplementary material, which is available to authorized users.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Efficacy and safety of psychostimulants for amphetamine and methamphetamine use disorders: a systematic review and meta-analysis

et al. 2016

View full text Add to dashboard Cite

show abstract

“…This is especially crucial since persons that smoke cigarettes may have an increased risk for amphetamine abuse [65,66] .…”

Section: Effect Of Bp On Anxietymentioning

confidence: 99%

Interaction of nicotinic receptors with bupropion: Structural, functional, and pre-clinical perspectives

Arias¹,

Biała²,

Kruk-Słomka³

et al. 2014

Receptor Clin Invest

View full text Add to dashboard Cite

Besides the antidepressant activity of bupropion (BP), preclinical studies in rodents provide evidence that this compound and its hydroxyl metabolites can attenuate nicotine withdrawal, reversing both the physical and negative affective aspects of nicotine abstinence. Co-interactions of BP with nicotine or other psychostimulants influence decrease anxiety-and cognitive-related processes. BP also attenuates the reinstatement of nicotine-induced conditioned place preference in rats caused by a priming dose of nicotine, morphine, cannabinoids, or ethanol.

show abstract

“…In one pilot RCT, researchers randomized 19 adolescents and young adults with methamphetamine abuse or dependence, ages 14 to 21 years, to bupropion or placebo for 8 weeks (57). Bupropion treatment, as compared to placebo, was associated with a greater number of positive urine toxicology screens for methamphetamine, suggesting this treatment may yield iatrogenic effects in youths.…”

Section: Introductionmentioning

confidence: 99%

Emerging Pharmacologic Treatments for Adolescent Substance Use: Challenges and New Directions

Miranda

Treloar

2016

Curr Addict Rep

View full text Add to dashboard Cite

Adolescence is a key period in the development of substance use and misuse. Substance use typically begins during adolescence and prevalence rates for many substance use disorders peak before age 21 years. Yet, despite clinical demand, treatments for youth rely almost entirely on psychosocial interventions that yield only modest benefit. One potential way to improve treatment effects is to augment the best available psychosocial interventions with pharmacotherapy. Although pharmacotherapy research has advanced care for adults with substance use disorders, no medication is indicated for adolescents and controlled trials with teenagers are scant. Optimizing treatments for youth will require closing this important gap in medication development research. In this paper we review the paucity of pharmacotherapy research for adolescent substance misuse, and we discuss how we can leverage human laboratory paradigms and technology to advance our understanding regarding if and how medications may improve treatment options for youths.

show abstract

Pilot Randomized Trial of Bupropion for Adolescent Methamphetamine Abuse/Dependence

Cited by 23 publications

References 10 publications

Efficacy and safety of psychostimulants for amphetamine and methamphetamine use disorders: a systematic review and meta-analysis

Efficacy and safety of psychostimulants for amphetamine and methamphetamine use disorders: a systematic review and meta-analysis

Interaction of nicotinic receptors with bupropion: Structural, functional, and pre-clinical perspectives

Emerging Pharmacologic Treatments for Adolescent Substance Use: Challenges and New Directions

Contact Info

Product

Resources

About